Literature DB >> 19779066

A murine model of myeloma that allows genetic manipulation of the host microenvironment.

Jessica A Fowler1, Gregory R Mundy, Seint T Lwin, Conor C Lynch, Claire M Edwards.   

Abstract

Multiple myeloma, and the associated osteolytic bone disease, is highly dependent upon cellular interactions within the bone marrow microenvironment. A major limitation of existing myeloma models is the requirement for a specific host strain of mouse, preventing molecular examination of the bone marrow microenvironment. The aim of the current study was to develop a model of myeloma in which the host microenvironment could be modified genetically. The Radl 5T murine model of myeloma is well characterized and closely mimics human myeloma. In the current study, we demonstrate 5T myeloma establishment in recombination activating gene 2 (RAG-2)-deficient mice, which have improper B- and T-cell development. Importantly, these mice can be easily bred with genetically modified mice to generate double knockout mice, allowing manipulation of the host microenvironment at a molecular level. Inoculation of 5TGM1 myeloma cells into RAG-2(-/-) mice resulted in myeloma development, which was associated with tumor growth within bone and an osteolytic bone disease, as assessed by microcomputed tomography (microCT), histology and histomorphometry. Myeloma-bearing RAG-2(-/-) mice displayed many features that were similar to both human myeloma and the original Radl 5T model. To demonstrate the use of this model, we have examined the effect of host-derived matrix metalloproteinase 9 (MMP-9) in the development of myeloma in vivo. Inoculation of 5TGM1 myeloma cells into mice that are deficient in RAG-2 and MMP-9 resulted in a reduction in both tumor burden and osteolytic bone disease when compared with RAG-2-deficient wild-type myeloma-bearing mice. The establishment of myeloma in RAG-2(-/-) mice permits molecular examination of the host contribution to myeloma pathogenesis in vivo.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19779066      PMCID: PMC2776114          DOI: 10.1242/dmm.003160

Source DB:  PubMed          Journal:  Dis Model Mech        ISSN: 1754-8403            Impact factor:   5.758


  24 in total

Review 1.  The 5TMM series: a useful in vivo mouse model of human multiple myeloma.

Authors:  K Asosingh; J Radl; I Van Riet; B Van Camp; K Vanderkerken
Journal:  Hematol J       Date:  2000

2.  Fluorescence-based staining for tartrate-resistant acidic phosphatase (TRAP) in osteoclasts combined with other fluorescent dyes and protocols.

Authors:  Luis Filgueira
Journal:  J Histochem Cytochem       Date:  2004-03       Impact factor: 2.479

3.  Animal model of human disease. Multiple myeloma.

Authors:  J Radl; J W Croese; C Zurcher; M H Van den Enden-Vieveen; A M de Leeuw
Journal:  Am J Pathol       Date:  1988-09       Impact factor: 4.307

4.  Production of metalloproteinase-7 (matrilysin) by human myeloma cells and its potential involvement in metalloproteinase-2 activation.

Authors:  S Barillé; R Bataille; M J Rapp; J L Harousseau; M Amiot
Journal:  J Immunol       Date:  1999-11-15       Impact factor: 5.422

5.  Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.

Authors:  Peter I Croucher; Raeve De Hendrik; Mark J Perry; Anja Hijzen; Claire M Shipman; Jennifer Lippitt; Jonathan Green; Eric Van Marck; Ben Van Camp; Karin Vanderkerken
Journal:  J Bone Miner Res       Date:  2003-03       Impact factor: 6.741

6.  Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease.

Authors:  Babatunde O Oyajobi; Giovanni Franchin; Paul J Williams; Donna Pulkrabek; Anjana Gupta; Steve Munoz; Barry Grubbs; Ming Zhao; Di Chen; Barbara Sherry; Gregory R Mundy
Journal:  Blood       Date:  2003-03-20       Impact factor: 22.113

Review 7.  Cancer statistics, 2004.

Authors:  Ahmedin Jemal; Ram C Tiwari; Taylor Murray; Asma Ghafoor; Alicia Samuels; Elizabeth Ward; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2004 Jan-Feb       Impact factor: 508.702

8.  Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo.

Authors:  Claire M Edwards; James R Edwards; Seint T Lwin; Javier Esparza; Babatunde O Oyajobi; Brandon McCluskey; Steven Munoz; Barry Grubbs; Gregory R Mundy
Journal:  Blood       Date:  2007-12-19       Impact factor: 22.113

9.  Idiopathic paraproteinemia. II. Transplantation of the paraprotein-producing clone from old to young C57BL/KaLwRij mice.

Authors:  J Radl; E D De Glopper; H R Schuit; C Zurcher
Journal:  J Immunol       Date:  1979-02       Impact factor: 5.422

10.  Cancer and the microenvironment: myeloma-osteoclast interactions as a model.

Authors:  Shmuel Yaccoby; Michele J Wezeman; Aminah Henderson; Michele Cottler-Fox; Qing Yi; Bart Barlogie; Joshua Epstein
Journal:  Cancer Res       Date:  2004-03-15       Impact factor: 12.701

View more
  27 in total

1.  Myeloma as a model for the process of metastasis: implications for therapy.

Authors:  Irene M Ghobrial
Journal:  Blood       Date:  2012-04-24       Impact factor: 22.113

2.  Osteoclast-derived matrix metalloproteinase-9 directly affects angiogenesis in the prostate tumor-bone microenvironment.

Authors:  Alexandre Bruni-Cardoso; Lindsay C Johnson; Robert L Vessella; Todd E Peterson; Conor C Lynch
Journal:  Mol Cancer Res       Date:  2010-03-23       Impact factor: 5.852

3.  Preclinical animal models of multiple myeloma.

Authors:  Seint T Lwin; Claire M Edwards; Rebecca Silbermann
Journal:  Bonekey Rep       Date:  2016-02-03

4.  Leflunomide regulates c-Myc expression in myeloma cells through PIM targeting.

Authors:  Ralf Buettner; Corey Morales; Enrico Caserta; Estelle Troadec; Emine G Gunes; Domenico Viola; Jihane Khalife; Hongzhi Li; Jonathan J Keats; Austin Christofferson; Xiwei Wu; Timothy W Synold; Joycelynne Palmer; James F Sanchez; Alexander Pozhitkov; Nagarajan Vaidehi; Guido Marcucci; Amrita Krishnan; Michael A Rosenzweig; Flavia Pichiorri; Steven T Rosen
Journal:  Blood Adv       Date:  2019-04-09

5.  Sprague Dawley Rag2-Null Rats Created from Engineered Spermatogonial Stem Cells Are Immunodeficient and Permissive to Human Xenografts.

Authors:  Fallon K Noto; Valeriya Adjan-Steffey; Goutham Narla; Tseten Y Jamling; Min Tong; Kameswaran Ravichandran; Wei Zhang; Angela Arey; Christopher B McClain; Eric Ostertag; Sahar Mazhar; Jaya Sangodkar; Analisa DiFeo; Jack Crawford
Journal:  Mol Cancer Ther       Date:  2018-09-11       Impact factor: 6.261

Review 6.  Tumor-host cell interactions in the bone disease of myeloma.

Authors:  Jessica A Fowler; Claire M Edwards; Peter I Croucher
Journal:  Bone       Date:  2010-07-13       Impact factor: 4.398

7.  Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease.

Authors:  Jessica A Fowler; Seint T Lwin; Matthew T Drake; James R Edwards; Robert A Kyle; Gregory R Mundy; Claire M Edwards
Journal:  Blood       Date:  2011-09-08       Impact factor: 22.113

Review 8.  Contributions of the host microenvironment to cancer-induced bone disease.

Authors:  Sam W Z Olechnowicz; Claire M Edwards
Journal:  Cancer Res       Date:  2014-03-05       Impact factor: 12.701

9.  Osteotropic Radiolabeled Nanophotosensitizer for Imaging and Treating Multiple Myeloma.

Authors:  Rui Tang; Alexander Zheleznyak; Matthew Mixdorf; Anchal Ghai; Julie Prior; Kvar C L Black; Monica Shokeen; Nathan Reed; Pratim Biswas; Samuel Achilefu
Journal:  ACS Nano       Date:  2020-04-06       Impact factor: 15.881

Review 10.  Navigating the bone marrow niche: translational insights and cancer-driven dysfunction.

Authors:  Michaela R Reagan; Clifford J Rosen
Journal:  Nat Rev Rheumatol       Date:  2015-11-26       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.